{
  "docId": "019de073-e60e-740c-a4d1-b8dd6fcd421d",
  "docSlug": "c76f9a1cfbf11e27618f62d901587aa3",
  "documentTitle": "Alkermes | Results Presentation Deck | 22 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 22,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "thesis_headline",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide outlines the strategic rationale for a spin-off company, focusing on clinical assets and platform technology.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-e60e-740c-a4d1-b8dd6fcd421d/8",
  "deckHref": "/decks/019de073-e60e-740c-a4d1-b8dd6fcd421d",
  "deckJsonHref": "/decks/019de073-e60e-740c-a4d1-b8dd6fcd421d.json",
  "deckAnchorHref": "/decks/019de073-e60e-740c-a4d1-b8dd6fcd421d#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.63,
        "w": 0.23,
        "x": 0.73,
        "y": 0.22
      },
      "kind": "callout",
      "text": "Nemvaleukin has broad potential clinical utility and offers an opportunity for significant value creation. Highly-experienced team with scientific and clinical trial expertise. Opportunity to attract oncology-focused investors.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18eee5bf-9058-4f92-bf8f-f74d395e87c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "* Also granted FDA Orphan Drug Designation; **In combination with pembrolizumab ‡ Assuming separation is effected through a spin-off of the oncology business into an independent, publicly-traded company",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab88e372-712b-40a4-bee5-54bf7dfb9ef5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.63,
        "x": 0.06,
        "y": 0.22
      },
      "kind": "list",
      "text": "Investment thesis anchored by potential medical and economic value of nemvaleukin alfa: Potential first-in-class IL-2 variant immunotherapy; Anti-tumor activity observed; Potential registration-enabling studies; Multiple routes of administration.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "51633aa0-0211-41af-8cea-5e38f046d92a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.63,
        "x": 0.06,
        "y": 0.65
      },
      "kind": "list",
      "text": "Sophisticated protein engineering platform capabilities and early-stage development assets: Tumor-targeted split IL-12 program; IL-18 program",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a7e93d7-bae2-431f-ba69-8438b0cf28ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "Post-Separation Oncology Co. Pure-play, Development-Stage Oncology Company",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb19e1d1-07d5-4115-b066-381aed713692",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 6,
      "beatId": "447f6264-8955-4168-914e-cfe1363597e7",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document proposes a solution (separation of oncology business) and presents expected outcomes to satisfy the audience's needs.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 6,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "a5a157cc-9029-478a-92e9-6838ab291f2a",
      "evidence": "The document presents a clear pattern of benefits, including enhanced profitability and clear value propositions.",
      "position": 0,
      "objective": "What are the benefits of separating the oncology business?",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.7,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}